Small cap biotech companies spend hundreds of millions of dollars and over ten years moving experimental drug candidates from concept to fully approved drugs. For late stage drug candidates, those in Phase III, positive or negative data can result in either massive gains or devastating declines in the sponsoring company's stock price. This "ultimate catalyst event" provides smart, organized & nimble option traders spectacular & consistent trading opportunities. In this unique book, the author provides individuals unfamiliar with the world of small cap biotech a fast, simplified and efficient approach to identify, analyze & execute trading strategies using options. The following topics, amongst others, are covered in this book: * Description of the FDA drug trial process, from pre-clinical to Phase III & beyond * Identification, categorization & organization of small cap biotech companies * Structured & streamlined approach to assess small cap biotech companies * Notes on trading strategy & tactics * Detailed description of option trading structures best suited for small cap biotech This book is an absolute "must have" for individuals thinking about trading in the fast paced and often confusing world of small cap biotech.
Les informations fournies dans la section « Synopsis » peuvent faire référence à une autre édition de ce titre.
T. Ayers Pelz was a trader on a major European bank's proprietary trading desk. He was responsible for a portfolio with limits of more than $200 million. Prior to proprietary trading, Mr. Pelz worked with several major investment banks in roles ranging from corporate finance, mergers and acquisitions to credit and business development. He has substantial international work experience in Asia, U.S., Europe and Latin America and was based in New York City, Bogotá (Colombia), Rio de Janeiro (Brazil) and Amsterdam (The Netherlands). Mr. Pelz currently resides in Denver, Colorado where he trades for his own account. He is married and has a young son.
Les informations fournies dans la section « A propos du livre » peuvent faire référence à une autre édition de ce titre.
EUR 10,19 expédition depuis Etats-Unis vers France
Destinations, frais et délaisEUR 5,67 expédition depuis Royaume-Uni vers France
Destinations, frais et délaisVendeur : -OnTimeBooks-, Phoenix, AZ, Etats-Unis
Etat : acceptable. Reading copy. May have signs of wear and previous use scuffs, library copy, highlighting, writing, and underlining . Dust jacket may be missing. 100% GUARANTEE! Shipped with delivery confirmation, if youâre not satisfied with purchase.Ships USPS Media Mail. N° de réf. du vendeur OTV.1450598536.A
Quantité disponible : 1 disponible(s)
Vendeur : THE SAINT BOOKSTORE, Southport, Royaume-Uni
Paperback / softback. Etat : New. This item is printed on demand. New copy - Usually dispatched within 5-9 working days 320. N° de réf. du vendeur C9781450598538
Quantité disponible : Plus de 20 disponibles
Vendeur : GreatBookPrices, Columbia, MD, Etats-Unis
Etat : New. N° de réf. du vendeur 9630756-n
Quantité disponible : Plus de 20 disponibles
Vendeur : GreatBookPrices, Columbia, MD, Etats-Unis
Etat : As New. Unread book in perfect condition. N° de réf. du vendeur 9630756
Quantité disponible : Plus de 20 disponibles
Vendeur : Best Price, Torrance, CA, Etats-Unis
Etat : New. SUPER FAST SHIPPING. N° de réf. du vendeur 9781450598538
Quantité disponible : 2 disponible(s)
Vendeur : GreatBookPricesUK, Woodford Green, Royaume-Uni
Etat : New. N° de réf. du vendeur 9630756-n
Quantité disponible : Plus de 20 disponibles
Vendeur : CitiRetail, Stevenage, Royaume-Uni
Paperback. Etat : new. Paperback. Small cap biotech companies spend hundreds of millions of dollars and over ten years moving experimental drug candidates from concept to fully approved drugs. For late stage drug candidates, those in Phase III, positive or negative data can result in either massive gains or devastating declines in the sponsoring company's stock price. This "ultimate catalyst event" provides smart, organized & nimble option traders spectacular & consistent trading opportunities. In this unique book, the author provides individuals unfamiliar with the world of small cap biotech a fast, simplified and efficient approach to identify, analyze & execute trading strategies using options. The following topics, amongst others, are covered in this book: * Description of the FDA drug trial process, from pre-clinical to Phase III & beyond * Identification, categorization & organization of small cap biotech companies * Structured & streamlined approach to assess small cap biotech companies * Notes on trading strategy & tactics * Detailed description of option trading structures best suited for small cap biotech This book is an absolute "must have" for individuals thinking about trading in the fast paced and often confusing world of small cap biotech. Shipping may be from our UK warehouse or from our Australian or US warehouses, depending on stock availability. N° de réf. du vendeur 9781450598538
Quantité disponible : 1 disponible(s)
Vendeur : Sunshine State Books, Lithia, FL, Etats-Unis
paperback. Etat : As New. Paperback--no flaws. N° de réf. du vendeur SF250312009G223
Quantité disponible : 1 disponible(s)
Vendeur : Treasure Island, Waltham, MA, Etats-Unis
paperback. Etat : New. N° de réf. du vendeur 53HN5000011O
Quantité disponible : 1 disponible(s)
Vendeur : clickgoodwillbooks, Indianapolis, IN, Etats-Unis
Etat : acceptable. Used - Acceptable: All pages and the cover are intact, but shrink wrap, dust covers, or boxed set case may be missing. Pages may include limited notes, highlighting, or minor water damage but the text is readable. Item may be missing bundled media. N° de réf. du vendeur 3O6WBH000CLA_ns
Quantité disponible : 1 disponible(s)